Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 26: | Line 26: | ||
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders | ! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders | ||
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]] | ! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]] | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* History of prior infection | * History of prior infection | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | ↓ | | align="center" style="background:#F5F5F5;" | ↓ | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
Line 42: | Line 42: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]] | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
*History of [[Medication|medications]] such as: | *History of [[Medication|medications]] such as: | ||
Line 54: | Line 54: | ||
** [[Linezolid]] | ** [[Linezolid]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 66: | Line 66: | ||
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication. | | align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication. | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* [[Thrombosis]] | * [[Thrombosis]] | ||
Line 83: | Line 83: | ||
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]]. | | align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]]. | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* History of prior [[infection]] or no history | * History of prior [[infection]] or no history | ||
Line 99: | Line 99: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Positive family history | * Positive family history | ||
Line 115: | Line 115: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | ||
| align="left" style="background:#F5F5F5;" | History of: | | align="left" style="background:#F5F5F5;" | History of: | ||
*[[Cancer]] | *[[Cancer]] | ||
Line 137: | Line 137: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | ||
| align="left" style="background:#F5F5F5;" |History of: | | align="left" style="background:#F5F5F5;" |History of: | ||
* [[Infections]] | * [[Infections]] | ||
Line 207: | Line 207: | ||
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]] | * Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]] | ||
|- | |- | ||
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]] | ! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]] | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Positive family history | * Positive family history | ||
Line 227: | Line 227: | ||
* Ristocetin - no aggregation | * Ristocetin - no aggregation | ||
|- | |- | ||
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]] | ! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]] | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Positive family history | * Positive family history | ||
Line 269: | Line 269: | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ||
| align="left" style="background:#F5F5F5 | | | align="left" style="background:#F5F5F5 " | | ||
* [[Chronic renal failure pathophysiology|Uremia]] | * [[Chronic renal failure pathophysiology|Uremia]] | ||
* [[Cardiopulmonary bypass]] | * [[Cardiopulmonary bypass]] | ||
Line 286: | Line 286: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Easy bruising | * Easy bruising | ||
Line 308: | Line 308: | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders | ||
! | ! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders | ||
! | ! colspan="2" | | ||
* Acute febrile illnesses | * Acute febrile illnesses | ||
* [[Cryoglobulinemia|Mixed cryoglobulinemia]] | * [[Cryoglobulinemia|Mixed cryoglobulinemia]] | ||
Line 334: | Line 334: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|- | |- | ||
! | ! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]] | ||
! | ! colspan="2" | | ||
* [[Marfan's syndrome|Marfan’s syndrome]] | * [[Marfan's syndrome|Marfan’s syndrome]] | ||
* [[Ehlers-Danlos syndrome]] | * [[Ehlers-Danlos syndrome]] | ||
Line 355: | Line 355: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|- | |- | ||
! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders | ! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders | ||
! | <ref name="pmid28966616" /> | ||
! | ! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency | ||
! colspan="2" |Different types of the [[fibrinogen]] disorders: | |||
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]] | * [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]] | ||
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]] | * [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]] | ||
Line 536: | Line 537: | ||
| | | | ||
|- | |- | ||
! | ! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]] | ||
! | ! colspan="2" |Types: | ||
* Sub unit A mutation disease (more common) | * Sub unit A mutation disease (more common) | ||
* Sub unit B mutation disease | * Sub unit B mutation disease | ||
Line 557: | Line 558: | ||
* The severity of factor XIII deficiency bleeds can be different in different patients | * The severity of factor XIII deficiency bleeds can be different in different patients | ||
|- | |- | ||
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]] | ! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]] | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency | ||
Line 617: | Line 618: | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases | ||
! colspan=" | ! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]] | ||
! | ! | ||
* [[Trauma]] | * [[Trauma]] | ||
* Burn | * Burn | ||
Line 639: | Line 640: | ||
| - | | - | ||
|- | |- | ||
! colspan=" | ! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]] | ||
! | ! | ||
* Bleeding after trauma | * Bleeding after trauma | ||
* [[Epistaxis]] | * [[Epistaxis]] | ||
Line 663: | Line 664: | ||
| - | | - | ||
|} | |} | ||
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table: | Different types of Von-Willebrand diseases can be differentiated from each other based on the following table: | ||
{| | {| | ||
Line 686: | Line 687: | ||
|- | |- | ||
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2 | ! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2 | ||
! align="center" style="background:#DCDCDC;" |2A | ! align="center" style="background:#DCDCDC;" |2A | ||
| align="center" style="background:#F5F5F5;" | Qualitative | | align="center" style="background:#F5F5F5;" | Qualitative | ||
| align="center" style="background:#F5F5F5;" | 10% | | align="center" style="background:#F5F5F5;" | 10% | ||
Line 739: | Line 740: | ||
|} | |} | ||
For more information on Von Willebrand disease, click [[ von willebrand disease | here]]. | For more information on Von Willebrand disease, click [[ von willebrand disease | here]]. | ||
<references /> |
Revision as of 15:54, 19 October 2018
Differential Diagnosis
Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.
These features have discussed in the below table:
Category | Sub-category | Diseases | History | Clinical manifestation | Laboratory testing | Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Platelet count | Bleeding time (BT) | Prothrombin time (PT) | Activated partial thromboplastin time (aPTT) | Thrombin time (TT) | ||||||
Platelet disorders | Thrombocytopenia | Infection-Induced thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | − | |
Medications-Induced thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | Most important part of treatment is discontinuing of the medication. | |||
Heparin-Induced thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | ↑ | For more information click here: Heparin-induced thrombocytopenia. | |||
Immune Thrombocytopenic Purpura (ITP) |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | − | |||
Inherited Thrombocytopenia |
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | − | |||
Thrombotic Thrombocytopenic Purpura (TTP) | History of:
|
+ | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | − | |||
Hemolytic Uremic Syndrome | History of: | + | + | + | + | + | + | ↓ | ↑ | Normal | Normal | Normal | − | |||
Thromobcytosis | Iron deficiency anemia
Inflammatory diseases |
− | − | − | − | +/- | +/- | ↑ | Normal or ↑ | Normal | Normal | Normal | − | |||
Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | Glanzmann’s thrombasthenia |
|
+ | + | + | + | − | Rare | Normal or ↓ | ↑ | Normal | Normal | Normal |
| |
Bernard-Soulier syndrome |
|
+ | + | + | + | − | − | Normal/↓ | ↑ | Normal | Normal | Normal |
| |||
Wiskott-Aldrich syndrome |
|
+ | + | + | + | − | − | Normal or ↓ | ↑ | Normal | Normal | Normal | ||||
Platelet storage pool disorder (SPD): |
|
+ | + | + | + | − | − | Normal or ↓ | ↑ | Normal | Normal | Normal |
| |||
Acquired Disorders of Platelet Function |
|
+ | + | + | + | +/- | +/- | Normal/↓ | ↑ | Normal | Normal | Normal | − | |||
Von Willebrand Disease [1] |
|
+ | + | + | + | +/- | +/- | ↑ | Normal | ↑ | ↑ | Normal | See the table below for the details about different types. | |||
Vessel wall disorders | Metabolic and Inflammatory Disorders |
|
|
− | + | + | +/- | - | - | Normal | ↑/Normal | Normal | Normal | Normal | - | |
Inherited Disorders of the Vessel Wall |
|
- | + | + | +/- | - | - | Normal | ↑/Normal | Normal | Normal | Normal | - | |||
Coagulation factor disorders | Fibrinogen deficiency | Different types of the fibrinogen disorders: |
|
- | - | + | + | +/- | + | Normal | ↑ | ↑ | ↑ | ↑ |
| |
Prothrombin deficiency |
|
+ | + | + | + | + | Normal | Normal | ↑ | ↑ | ↑ | - | ||||
Factor V deficiency |
|
_ | + | + | + | + | Normal | ↑ | ↑ | ↑ | Normal | The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding. | ||||
Factor VII deficiency |
|
+ | + | + | Normal | ↑ | Normal | Normal | Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy | |||||||
Factor X deficiency |
|
+ | + | + | + | + | Normal | Normal | ↑ | ↑ | Normal | - | ||||
Factor XII deficiency |
|
_ | _ | _ | _ | _ | Normal | Normal | Normal | ↑ | Normal | |||||
High molecular weight kininogen (HMWK) deficiency |
|
_ | _ | _ | _ | _ | Normal | Normal | Normal | ↑ | Normal | |||||
Prekallikrein deficiency |
|
_ | _ | _ | _ | _ | Normal | Normal | Normal | ↑ | Normal | |||||
Factor XIII deficiency | Types:
|
|
-/+ | -/+ | -/+ | -/+ | -/+ | -/+ | Normal | Normal | Normal/↑ | Normal | Normal |
| ||
Hemophilia | Type A deficiency |
|
- | - | - | + | + | + | Normal | Normal | Normal | ↑ | Normal | - | ||
Type B deficiency |
|
- | - | - | + | + | + | Normal | Normal | Normal | ↑ | Normal | - | |||
Type C deficiency |
|
- | - | - | + | Rare | Rare | Normal | Normal | Normal | ↑ | Normal | - | |||
Rare diseases | Disseminated Intravascular Coagulation |
|
+ | + | + | + | + | + | ↓ | ↑ | ↑ | ↑ | Normal | - | ||
Vitamin K Deficiency |
|
+ | - | + | + | + | + | Normal | ↑ | ↑ | Normal or mildly prolonged | Normal | - |
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:
Type of VWD | Type of factor deficiency | Prevalence | Inheritance pattern | Clinical manifestations | VWF activity | RIPA | Factor VIII | |
---|---|---|---|---|---|---|---|---|
Type 1 | Quantitative/ partial | 60-70% | AD |
|
↓ | ↓ | ↓ | |
Type 2 | 2A | Qualitative | 10% | AD/AR |
|
↓ | ↓ | N or ↓ |
2B | Qualitative | 5% | AD |
|
↓ | ↑ | N or ↓ | |
2M | Qualitative | <1% | AD/AR |
|
↓ | ↓ | N or ↓ | |
2N | Qualitative | <1% | AR |
|
N | N | ↓ | |
Type 3 | Complete deficiency | 1-2% | AR |
|
Absent | ↓ | Low, 1-10% |
For more information on Von Willebrand disease, click here.
- ↑ Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD (November 2014). "Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project". Haemophilia. 20 (6): 831–5. doi:10.1111/hae.12503. PMC 4251588. PMID 25196510.
- ↑ Invalid
<ref>
tag; no text was provided for refs namedpmid28966616